A Phase 1 interventional study of iMET and MET in Drug Abuse, Alcohol Abuse and Nicotine Dependence, sponsored by Boston Children's Hospital. Withdrawn at 1 site in United States. Open to participants aged 12 Years to 21 Years. Per ClinicalTrials.gov, last updated 2017-04-12.
Sponsored by Boston Children's Hospital · Phase 1, Interventional, and Treatment
The purpose of this study is to test the effects of a computerized, self-directed Motivational Enhancement Therapy program for adolescent substance use (iMET), in comparison to clinician-delivered MET and Treatment As Usual (TAU), on treatment engagement and substance use. The investigators hypothesize that both iMET and MET will be more effective than TAU in engaging/retaining patients in treatment and in reducing substance use during a 12-month follow-up period. The investigators also hypothesize that Self-directed iMET will be as effective as the clinician-guided MET in increasing treatment engagement and abstinence during the 12-months follow-up period.
2,181 studies on the registry are indexed under Substance-Related Disorders; 399 are open to participants now.
Browse Substance-Related Disorders studies →Boston Children's Hospital is the lead sponsor of 607 studies on the registry; 148 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 19 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will receive the usual care from the treatment program
Participants will complete a self-guided computerized Motivational Enhancement Therapy
Behavioral: iMET
Clinician-delivered Motivational Enhancement Therapy
Behavioral: MET
Self-completed, computerized motivational enhancement therapy
Clinician-delivered Motivational Enhancement Therapy
Treatment engagement
We will compare the number of individual visits in the program, the number of group sessions completed, and the number of urine screens completed during a 12 month follow-up period by each participant in the three study arms.
Time frame: 12 months
Days abstinent
We will calculate the past-90-days number of days abstinent from any substance use and from the primary substance and the number of weeks abstinent from any substance use.
Time frame: past-90-days
Driving/Riding Risk
We will compare group trends in prevalence and frequency of past-90-days Driving while impaired or Riding with an impaired driver.
Time frame: past-90-days
HIV Risk Behavior
We will compare group trends in prevalence and frequency of past-90-days HIV Risk Behaviors.
Time frame: past-90-days
Treatment process/quality
We will compare completion of the 2 MET sessions, and completion of the third follow-up visit between the iMET and MET conditions.
Time frame: 60 days
The record gives a start of Oct 2013 and a primary completion of Jan 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.